Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Paull

Showing results (51-60 of 63) with videos related to

Pageof 7
Sort By:
Scientific Reports|September 11, 2024
Astodrimer sodium nasal spray forms a barrier to SARS-CoV-2 in vitro and preserves normal mucociliary function in human nasal epitheliumJeremy R A Paull, Carolyn A Luscombe, Aynaz Seta, et al.
Drug Development and Industrial Pharmacy|December 2, 2008
Formulating a sulfonated antiviral dendrimer in a vaginal microbicidal gel having dual mechanisms of actionRussell J Mumper, Michael A Bell, David R Worthen, et al.
Plos One|May 5, 2020
A phase 2, double-blind, multicenter, randomized, placebo-controlled, dose‑ranging study of the efficacy and safety of Astodrimer Gel for the treatment of bacterial vaginosisArthur S Waldbaum, Jane R Schwebke, Jeremy R A Paull, et al.
Molecular Pharmaceutics|August 2, 2005
Dendrimers as drugs: discovery and preclinical and clinical development of dendrimer-based microbicides for HIV and STI preventionTom D McCarthy, Peter Karellas, Scott A Henderson, et al.
European Journal of Obstetrics & Gynecology and Reproductive Biology: X|February 4, 2021
A phase 3, randomized, controlled trial of Astodrimer 1% Gel for preventing recurrent bacterial vaginosisJane R Schwebke, Belvia A Carter, Arthur S Waldbaum, et al.
The Journal of Antimicrobial Chemotherapy|November 1, 1994
A multicentre study of the in-vitro activity of cefotaxime, cefuroxime, ceftazidime, ofloxacin and ciprofloxacin against blood and urinary pathogensS G Amyes, D R Baird, D W Crook, et al.
Antiviral Research|April 5, 2011
Virucidal activity of the dendrimer microbicide SPL7013 against HIV-1Sushama Telwatte, Katie Moore, Adam Johnson, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 14, 2009
A randomized controlled trial of the safety of candidate microbicide SPL7013 gel when applied to the penisMarcus Y Chen, Iona Y Millwood, Handan Wand, et al.
Plos One|September 22, 2011
SPL7013 Gel (VivaGel®) retains potent HIV-1 and HSV-2 inhibitory activity following vaginal administration in humansClare F Price, David Tyssen, Secondo Sonza, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology|December 9, 2019
Two phase 3, double-blind, placebo-controlled studies of the efficacy and safety of Astodrimer 1% Gel for the treatment of bacterial vaginosisSteven E Chavoustie, Belvia A Carter, Arthur S Waldbaum, et al.
Pageof 7

Showing results (51-60 of 63) with videos related to

Sort By:
Pageof 7
Scientific Reports|September 11, 2024
Astodrimer sodium nasal spray forms a barrier to SARS-CoV-2 in vitro and preserves normal mucociliary function in human nasal epitheliumJeremy R A Paull, Carolyn A Luscombe, Aynaz Seta, et al.
Drug Development and Industrial Pharmacy|December 2, 2008
Formulating a sulfonated antiviral dendrimer in a vaginal microbicidal gel having dual mechanisms of actionRussell J Mumper, Michael A Bell, David R Worthen, et al.
Plos One|May 5, 2020
A phase 2, double-blind, multicenter, randomized, placebo-controlled, dose‑ranging study of the efficacy and safety of Astodrimer Gel for the treatment of bacterial vaginosisArthur S Waldbaum, Jane R Schwebke, Jeremy R A Paull, et al.
Molecular Pharmaceutics|August 2, 2005
Dendrimers as drugs: discovery and preclinical and clinical development of dendrimer-based microbicides for HIV and STI preventionTom D McCarthy, Peter Karellas, Scott A Henderson, et al.
European Journal of Obstetrics & Gynecology and Reproductive Biology: X|February 4, 2021
A phase 3, randomized, controlled trial of Astodrimer 1% Gel for preventing recurrent bacterial vaginosisJane R Schwebke, Belvia A Carter, Arthur S Waldbaum, et al.
The Journal of Antimicrobial Chemotherapy|November 1, 1994
A multicentre study of the in-vitro activity of cefotaxime, cefuroxime, ceftazidime, ofloxacin and ciprofloxacin against blood and urinary pathogensS G Amyes, D R Baird, D W Crook, et al.
Antiviral Research|April 5, 2011
Virucidal activity of the dendrimer microbicide SPL7013 against HIV-1Sushama Telwatte, Katie Moore, Adam Johnson, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 14, 2009
A randomized controlled trial of the safety of candidate microbicide SPL7013 gel when applied to the penisMarcus Y Chen, Iona Y Millwood, Handan Wand, et al.
Plos One|September 22, 2011
SPL7013 Gel (VivaGel®) retains potent HIV-1 and HSV-2 inhibitory activity following vaginal administration in humansClare F Price, David Tyssen, Secondo Sonza, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology|December 9, 2019
Two phase 3, double-blind, placebo-controlled studies of the efficacy and safety of Astodrimer 1% Gel for the treatment of bacterial vaginosisSteven E Chavoustie, Belvia A Carter, Arthur S Waldbaum, et al.
Pageof 7